Statement from Ralph G. Neas, President and CEO, GPhA on FDA Decision on Abuse-Deterrent Formulations of OxyContin

Published Online: Wednesday, April 17, 2013
Follow Pharmacy_Times:
PRESS RELEASE

WASHINGTON, DC (April 17, 2013) — “We share the Agency’s goal of addressing prescription opioid abuse, and using a science-based approach to take on this complex problem. At the same time, we recognize the importance of balancing patient access to medicine with efforts to minimize abuse.

Yesterday’s decision from the FDA provides clear guidance on what is considered an abuse-deterrent formulation for OxyContin, information that GPhA and its member companies have been seeking since 2010.

Along with the draft guidance on abuse-deterrent formulations made available in January, this represents a beginning for other brand and generic manufacturers seeking to create these formulations.

We will continue to work with FDA to make progress on this front, contributing our comments to the public commentary period to hone the standards, and offering our manufacturers’ perspective.

As the science of abuse deterrence evolves, we look forward to making contributions to this new field.”

Related Articles
Deaths related to oxycodone overdose dropped 25% in Florida after the state adopted a Prescription Drug Monitoring Program to track controlled substance dispensing.
Generic drugs are cheap, effective, and FDA approved. So, what's the problem?
The FDA has outlined the type of studies opioids need to complete to win approval for abuse-deterrence.
Responding to the growing number of deaths related to prescription opioid overdose, the US Department of Health and Human Services recently announced new opioid abuse countermeasures.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$